Market Closed -
London S.E.
11:35:26 2024-07-11 am EDT
|
5-day change
|
1st Jan Change
|
14.5
GBX
|
0.00%
|
|
0.00%
|
-68.48%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
64.81
|
26.2
|
14.92
|
5.742
|
-
|
-
|
Enterprise Value (EV)
2 |
50.99
|
18.79
|
14.92
|
5.142
|
5.242
|
4.442
|
P/E ratio
|
-5.29
x
|
-3.42
x
|
-
|
-1.37
x
|
45.7
x
|
6.78
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
331
x
|
1,092
x
|
324
x
|
57.4
x
|
11.5
x
|
4.78
x
|
EV / Revenue
|
261
x
|
783
x
|
324
x
|
51.4
x
|
10.5
x
|
3.7
x
|
EV / EBITDA
|
-9.46
x
|
-2.75
x
|
-2.88
x
|
-1.43
x
|
-2.1
x
|
-2.34
x
|
EV / FCF
|
-5.43
x
|
-3.17
x
|
-
|
-1.43
x
|
-
|
4.94
x
|
FCF Yield
|
-18.4%
|
-31.6%
|
-
|
-70%
|
-
|
20.3%
|
Price to Book
|
3.12
x
|
2.05
x
|
-
|
0.94
x
|
0.89
x
|
0.77
x
|
Nbr of stocks (in thousands)
|
25,481
|
25,486
|
25,486
|
30,659
|
-
|
-
|
Reference price
3 |
1.880
|
0.8500
|
0.4600
|
0.1450
|
0.1450
|
0.1450
|
Announcement Date
|
3/28/22
|
2/20/23
|
4/4/24
|
-
|
-
|
-
|
1GBP in Million2USD in Million3GBP Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
0.1956
|
0.024
|
0.046
|
0.1
|
0.5
|
1.2
|
EBITDA
1 |
-
|
-5.39
|
-6.84
|
-5.19
|
-3.6
|
-2.5
|
-1.9
|
EBIT
1 |
-
|
-5.714
|
-6.555
|
-
|
-3.8
|
-2.7
|
-2.1
|
Operating Margin
|
-
|
-2,921.7%
|
-27,312.5%
|
-
|
-3,800%
|
-540%
|
-175%
|
Earnings before Tax (EBT)
1 |
-
|
-7.428
|
-7.602
|
-
|
-3.9
|
0.1
|
0.8
|
Net income
1 |
-4.839
|
-7.444
|
-7.606
|
-
|
-3.9
|
0.1
|
0.8
|
Net margin
|
-
|
-3,806.41%
|
-31,691.67%
|
-
|
-3,900%
|
20%
|
66.67%
|
EPS
2 |
-0.0412
|
-0.3556
|
-0.2484
|
-
|
-0.1061
|
0.003170
|
0.0214
|
Free Cash Flow
1 |
-
|
-9.386
|
-5.93
|
-
|
-3.6
|
-
|
0.9
|
FCF margin
|
-
|
-4,799.43%
|
-24,708.33%
|
-
|
-3,600%
|
-
|
75%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
112.5%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
7/13/21
|
3/28/22
|
2/20/23
|
4/4/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
13.8
|
7.41
|
-
|
0.6
|
0.5
|
1.3
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-9.39
|
-5.93
|
-
|
-3.6
|
-
|
0.9
|
ROE (net income / shareholders' equity)
|
-
|
-31.5%
|
-45.7%
|
-51.4%
|
-66%
|
1.7%
|
11.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
0.6000
|
0.4100
|
-
|
0.1500
|
0.1600
|
0.1900
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1.85
|
0.09
|
-
|
0.1
|
0.1
|
0.1
|
Capex / Sales
|
-
|
944.61%
|
354.17%
|
-
|
100%
|
20%
|
8.33%
|
Announcement Date
|
7/13/21
|
3/28/22
|
2/20/23
|
4/4/24
|
-
|
-
|
-
|
Last Close Price
0.145
GBP Average target price
2.2
GBP Spread / Average Target +1,417.24% Consensus |
1st Jan change
|
Capi.
|
---|
| -68.48% | 5.71M | | -39.39% | 8.36B | | +10.79% | 3.38B | | +3.81% | 2.18B | | -25.96% | 1.82B | | -17.96% | 1.64B | | +31.30% | 1.03B | | +31.42% | 752M | | -12.01% | 689M | | -20.61% | 516M |
Bio Diagnostics & Testing
|